Halper Sadeh LLC Launches Investigation Into STAA, YMAB, and DNOW Shareholder Matters Halper Sadeh LLC, a law firm for investors, is probing STAAR Surgical, Y-mAbs Therapeutics, and DNOW for potential violations of securities laws. Shareholders can explore their rights and options.

Halper Sadeh LLC Launches Investigation Into STAA, YMAB, and DNOW Shareholder Matters #USA #New_York #Halper_Sadeh #STAA #YMAB

Y-mAbs (YMAB) Q2 Revenue Falls 14% | The Motley Fool

#YMAB #c15f52bd-32ff-4af8-8814-5c8d5505c41d #data-news

Origin | Interest | Match

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments Y-mAbs Therapeutics (NASDAQ: YMAB) reported its Q2 2025 financial results and announced a significant acquisition deal. SERB Pharmaceuticals will acquire Y-mAbs for $412.0 million ($8.60 per share in cash), representing a 105% premium to Y-mAbs' closing price on August 4, 2025. The transaction is expected to close by Q4 2025.Q2 2025 financial highlights include total revenues of $19.5 million, a 14% decrease from Q2 2024, primarily due to lower DANYELZA® product revenues. The company reported a net loss of $3.2 million ($0.07 per share), improved from a $9.2 million loss in Q2 2024. Cash position stands at $62.3 million as of June 30, 2025.DANYELZA net product revenues totaled $19.0 million, with U.S. revenues at $14.3 million (6% decrease) and Ex-U.S. revenues at $4.7 million. The decline was attributed to decreased patient volume due to clinical study enrollments and competition.

#YMAB Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

www.stocktitan.net/news/YMAB/y-m-abs-report...

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 Y-mAbs Therapeutics (NASDAQ:YMAB), a commercial-stage biopharmaceutical company specializing in antibody-based cancer therapeutics, will release its Q2 2025 financial results on Friday, August 8, 2025, before market open.Due to the previously announced transaction with SERB Pharmaceuticals affiliates, the company will not conduct an earnings conference call for this quarter.

#YMAB Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

www.stocktitan.net/news/YMAB/y-m-abs-to-ann...

2/ 📈 GANADORAS

Palantir: +7.9% Ingresos récord superan las expectativas de analistas #PLTR

Y-mAbs: +105% Será adquirida por SERB Pharmaceuticals con una prima enorme #YMAB

Staar Surgical: +51% Adquirida por Alcon en un acuerdo de $1.5 mil mm #STAA

JUST IN: ( NASDAQ: #YMAB ) US Companies Moving the Markets, Evening edition <br>Tue, Aug 05, 2025 as of 4:00 pm ET

JUST IN: ( NASDAQ: #YMAB ) US Companies Moving the Markets, Morning edition <br>Tue, Aug 05, 2025 as of 10.00 am ET

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics Y-mAbs Therapeutics (NASDAQ:YMAB) has entered into a definitive merger agreement with SERB Pharmaceuticals in an all-cash transaction valued at approximately $412 million. Under the agreement, SERB will acquire all outstanding YMAB shares for $8.60 per share, representing a 105% premium to Y-mAbs' closing price on August 4, 2025.The acquisition includes Y-mAbs' lead commercial asset DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma. The transaction strengthens SERB's rare oncology portfolio, which includes Voraxaze®, Vistogard®, and Xermelo®.The deal, unanimously approved by Y-mAbs' Board, is expected to close by Q4 2025. Approximately 16% of Y-mAbs stockholders have agreed to tender their shares. SERB will commence the tender offer by August 19, 2025, subject to customary conditions including Hart-Scott-Rodino approval.

#YMAB SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

www.stocktitan.net/news/YMAB/serb-pharmaceu...

Leading Indicators, Monday August 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Mon Aug 4th - #CPHI #PC #MURA #YMAB #WHLC #TTEC #MDWD #BCDA #SBXD - More: crystalequityresearch.com/leading-indi... - #smallcap

Y-mAbs Highlights Radiopharmaceutical Progress and Pipeline Expansion at R&D Update Phase 1 SADA Program Demonstrates Safety and Tumor Targeting; Company Unveils Broader Oncology Development Strategy Y-mAbs Therapeutics (Nasdaq: YMAB) shared

#YMAB highlights major strides in radiopharmaceuticals and pipeline growth at its latest R&D update. A promising leap in targeted cancer treatment.
#Biotech #Radiopharma #YMabs #CancerResearch
prismmarketview.com/y-mabs-highl...

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline Y-mAbs Therapeutics (YMAB) provided updates on its Radiopharmaceutical Business Unit during a virtual R&D update. The company reported positive results from Part A of Trial 1001, validating their GD2-SADA platform in treating patients with recurrent or refractory metastatic solid tumors. Key findings showed that GD2-SADA was safe and well-tolerated, with no treatment-related serious adverse events. The company plans to advance with "Proteus," a novel universal radiohapten, and will initiate a Bridge study (Part 2A) in 1H 2026, followed by Part B in 1H 2027. Y-mAbs is expanding its radiopharmaceutical pipeline to focus on lung cancer, women's cancers, and gastrointestinal cancers, with plans to file an IND for its first molecular imaging asset by end of 2025.

#YMAB Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

www.stocktitan.net/news/YMAB/y-m-abs-hosts-...

News; ( NASDAQ: #YMAB ) Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment First-in-human trial achieves milestone for innovative radioimmunotherapy targeting multiple aggressive cancers. Critical data readout coming May 28. Get trial insights.

#YMAB Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

www.stocktitan.net/news/YMAB/y-m-abs-presen...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bullish moving average convergence divergence crossovers, Tue May 13th - #YMAB #AMBR #CDNA #IMRX #MERC #NWPX #OXSQ #PHAT #TIPT #XBIT #USAC #RYI #PSTL #PKST #OLP #NINE #HBB #FUBO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments Y-mAbs Therapeutics (YMAB) reported its Q1 2025 financial results with total revenues of $20.9 million, up 5% year-over-year. DANYELZA net product revenues increased 8% to $20.9 million, with U.S. revenues declining 28% to $13.4 million while Ex-U.S. revenues grew by $6.7 million to $7.5 million. The company reported a net loss of $5.2 million ($0.12 per share), improved from $6.6 million loss in Q1 2024. Cash position stands at $60.3 million, expected to fund operations into 2027. Notable developments include NCCN Guidelines inclusion of DANYELZA for neuroblastoma treatment and first patient dosing in CD38-SADA Phase 1 trial for non-Hodgkin Lymphoma. Management reiterated FY2025 revenue guidance of $75-90 million and expects Q2 2025 revenues between $17-19 million.

#YMAB Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

www.stocktitan.net/news/YMAB/y-m-abs-report...

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) Y-mAbs Therapeutics (NASDAQ: YMAB) announced that its drug naxitamab-gqgk (DANYELZA®) has been included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines as a Category 2A treatment option for high-risk neuroblastoma. The drug, which received FDA accelerated approval in November 2020, is used in combination with GM-CSF for treating relapsed or refractory high-risk neuroblastoma in pediatric patients (1+ years) and adults.DANYELZA's FDA approval was based on efficacy results from two single-arm, open-label trials: Study 201 and Study 12-230. The drug was developed by Memorial Sloan Kettering Cancer Center and is exclusively licensed to Y-mAbs. This NCCN recognition reinforces DANYELZA's position as a leading anti-GD2 therapy for treating relapsed/refractory high-risk neuroblastoma.

#YMAB Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

www.stocktitan.net/news/YMAB/y-m-abs-announ...

Cancer Treatment Pioneer Y-mAbs Announces Q1 2025 Earnings Date: Key Updates Coming May 13 Biotech firm Y-mAbs schedules Q1 2025 earnings call for May 13, 8:00 AM ET. Get insights on latest radioimmunotherapy developments. See financial details.

#YMAB Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

www.stocktitan.net/news/YMAB/y-m-abs-to-ann...

Revolutionary Cancer Treatment: Y-mAbs CD38-SADA Therapy Achieves 20X Faster Clearance Rate in Latest Trial New preclinical data validates Y-mAbs' innovative radioimmunotherapy platform for NHL treatment. Phase 1 trial now underway with first patient dosed. See full results.

#YMAB Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

www.stocktitan.net/news/YMAB/y-m-abs-presen...

Groundbreaking Radioimmunotherapy: Y-mAbs Launches First-in-Human Trial for Advanced Lymphoma Treatment First patient receives innovative CD38-SADA pre-targeted therapy for resistant lymphoma. Exclusive technology shows promise in targeted treatment. See trial details.

#YMAB Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

www.stocktitan.net/news/YMAB/y-m-abs-announ...

News; ( NASDAQ: #YMAB ) Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments Y-mAbs Therapeutics (YMAB) reported Q4 2024 financial results with total revenues of $26.5 million, up 13% year-over-year, and full-year 2024 revenues of $87.7 million, a 3% increase from 2023.Key highlights include:U.S. DANYELZA revenues declined 12% in Q4 and 3% for full-year 2024International DANYELZA revenues grew 78% in Q4 and 16% for full-year 2024Cash position of $67.2 million as of December 31, 2024Net loss of $6.8 million in Q4 2024 ($0.15 per share)The company established two business units in January 2025 for Radiopharmaceuticals Platform and DANYELZA commercialization. 2025 guidance projects total revenues between $75-90 million and operating expenses between $116-121 million. Cash runway expected into 2027.

#YMAB Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

www.stocktitan.net/news/YMAB/y-m-abs-report...

Can Y-mAbs' Neuroblastoma Therapy Turn 93% Survival Rate Into FDA Approval? Naxitamab with GM-CSF achieved 50% response rate in high-risk neuroblastoma patients with 93% one-year survival, despite some infusion-related adverse events.

#YMAB Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

www.stocktitan.net/news/YMAB/y-m-abs-announ...

When Will Y-mAbs Report Q4 Earnings? Key Date for Biotech Investors Commercial-stage biotech Y-mAbs schedules Q4 and FY2024 earnings release, with analyst call at 8 AM ET. Key updates on radioimmunotherapy pipeline expected.

#YMAB Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

www.stocktitan.net/news/YMAB/y-m-abs-to-ann...

Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results Y-mAbs presents key pharmacokinetics findings for GD2-SADA cancer therapy, demonstrating optimal tumor exposure and informing ongoing Phase 1 trial dosing strategy.

#YMAB Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

www.stocktitan.net/news/YMAB/y-m-abs-presen...

Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth Y-mAbs announces strategic reorganization with promising GD2-SADA trial results, strong $67M cash position through 2027, and establishment of dedicated business units despite workforce changes.

#YMAB Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

www.stocktitan.net/news/YMAB/correcting-rep...

Y-mAbs Therapeutics Hits $88M Revenue Target, Unveils Strategic Split Into Two Business Units Y-mAbs reports $88M revenue for 2024, announces reorganization into Radiopharmaceuticals and DANYELZA units. GD2-SADA trial shows promising safety data with $67M cash runway.

#YMAB Y-mAbs Provides Strategic Business Update and 2025 Priorities

www.stocktitan.net/news/YMAB/y-m-abs-provid...

Y-mAbs' CD38-SADA Shows Promising Anti-Tumor Results in NHL Treatment at ASH Meeting Y-mAbs presents encouraging preclinical data for CD38-SADA platform in Non-Hodgkin Lymphoma treatment, showcasing selective binding and launching Phase 1 trial with Lu177-DOTA.

#YMAB Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

#news #stocks #StockMarket

www.stocktitan.net/news/YMAB/y-m-abs-presen...

News; ( NASDAQ: #YMAB ) Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference

#StockMarket #News

JUST IN: ( NASDAQ: #YMAB ) Expected earnings - Y-mAbs Therapeutics Inc.

#StockMarket #News